LDL Particle Number Measured Using NMR Clinical Analyzer
|
By LabMedica International staff writers Posted on 25 Aug 2014 |
|
Image: The Vantera Clinical Analyzer offers the technology that has the ability to directly enumerate low-density lipoprotein (LDL) particle numbers (Photo courtesy of LipoScience).
Fully-automated high-throughput nuclear magnetic resonance (NMR) spectroscopy has been developed to enable measurements in a clinical laboratory setting.
NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant.
Scientists at LipoScience Inc. (Raleigh, NC, USA) purchased serum pools and controls from Solomon Park Research Laboratories (Kirkland, WA, USA). Controls were prepared by identifying serum samples with high and low lipoprotein ranges. Additional serum pools were prepared in-house from donor subjects identified at LipoScience or Mayo Clinic (Rochester, MN, USA). NMR spectra were acquired on the NMR Profiler (Bruker Bio-Spin; Billerica, MA, USA) or the Vantera Clinical Analyzer (Agilent Technologies; Santa Clara, CA, USA), both equipped with 400 MHz 1H NMR spectrometers.
The sensitivity and linearity were established within the range of 300–3,500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2,282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only two exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation.
The authors concluded that the successful development of a method to measure LDL-P on a fully automated platform allows NMR technology dissemination into the routine, clinical laboratory setting and creates the opportunity for NMR-based testing across a broader range of clinical applications. They point out that, several leading national reference laboratories and large hospital system laboratories have successfully integrated the Vantera into their clinical laboratory operations. The study was published on July 28, 2014, in the journal Clinical Biochemistry.
Related Links:
LipoScience Inc.
Mayo Clinic
Bruker Bio-Spin
NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant.
Scientists at LipoScience Inc. (Raleigh, NC, USA) purchased serum pools and controls from Solomon Park Research Laboratories (Kirkland, WA, USA). Controls were prepared by identifying serum samples with high and low lipoprotein ranges. Additional serum pools were prepared in-house from donor subjects identified at LipoScience or Mayo Clinic (Rochester, MN, USA). NMR spectra were acquired on the NMR Profiler (Bruker Bio-Spin; Billerica, MA, USA) or the Vantera Clinical Analyzer (Agilent Technologies; Santa Clara, CA, USA), both equipped with 400 MHz 1H NMR spectrometers.
The sensitivity and linearity were established within the range of 300–3,500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2,282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only two exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation.
The authors concluded that the successful development of a method to measure LDL-P on a fully automated platform allows NMR technology dissemination into the routine, clinical laboratory setting and creates the opportunity for NMR-based testing across a broader range of clinical applications. They point out that, several leading national reference laboratories and large hospital system laboratories have successfully integrated the Vantera into their clinical laboratory operations. The study was published on July 28, 2014, in the journal Clinical Biochemistry.
Related Links:
LipoScience Inc.
Mayo Clinic
Bruker Bio-Spin
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
ESR Analyzer
iSED PRO
New
Steam Sterilizer
Hi Vac II Line
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
- Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Channels
Molecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Microbiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
Pathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
Technology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more
